A5057084037- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Hemoglobinopathies and Related Disorders
- Neutropenia and Cancer Infections
- Kruppel-like factors research
- Hematopoietic Stem Cell Transplantation
- Peptidase Inhibition and Analysis
- Platelet Disorders and Treatments
- HIV/AIDS drug development and treatment
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- CNS Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Cancer therapeutics and mechanisms
- Fungal Infections and Studies
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
Federico II University Hospital
2016-2025
University of Naples Federico II
2016-2025
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
2025
University of Cagliari
2025
Ceinge Biotecnologie Avanzate (Italy)
2006-2024
Bristol-Myers Squibb (Switzerland)
2022
Regeneron (United States)
2022
AstraZeneca (Brazil)
2022
Triangle
2022
Istituto di Ematologia di Bologna
2022
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have clinical benefit in patients with polycythemia vera phase study. We conducted 3 open-label study evaluate the efficacy safety of ruxolitinib versus standard therapy who had an inadequate response or unacceptable side effects from hydroxyurea.We randomly assigned phlebotomy-dependent splenomegaly, 1:1 ratio, receive (110 patients) (112 patients). The primary end point both hematocrit control through week 32 at least 35%...
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Abstract Purpose: ABL kinase domain mutations have been implicated in the resistance to BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients. Experimental Design: Using denaturing high-performance liquid chromatography and sequencing, we screened for 370 Ph+ patients with evidence hematologic or cytogenetic imatinib. Results: Mutations were found 127 297 (43%) evaluable 27% chronic-phase (14% treated frontline; 31% post-IFN failure), 52% accelerated-phase...
Imatinib slows development of chronic myeloid leukemia (CML). However, available information on morbidity and mortality is largely based sponsored trials, whereas independent long-term field studies are lacking. Consecutive CML patients who started imatinib treatment before 2005 were in complete cytogenetic remission (CCyR) after 2 years (±3 months) eligible for enrollment the multicenter Long-Term (Side) Effects (ILTE) study. Incidence first serious nonserious adverse events loss CCyR...
Point mutations within the ABL kinase domain of BCR-ABL gene have been associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients. To shed further light on frequency, distribution, and prognostic significance mutations, we retrospectively analyzed a homogeneous cohort late phase CML patients who showed primary cytogenetic imatinib.Using denaturing high-performance liquid chromatography (D-HPLC) sequencing, screened for total 178 bone marrow and/or...
Purpose The causes of the aggressive nature BCR-ABL1–positive adult acute lymphoblastic leukemia (ALL) are unknown. To identify, at submicroscopic level, oncogenic lesions that cooperate with BCR-ABL1 to induce ALL, we performed an investigation genomic copy number alterations using single nucleotide polymorphism array, polymerase chain reaction, and sequencing candidate genes. Patients Methods Eighty-three patients de novo Philadelphia chromosome (Ph) –positive ALL were enrolled onto...
Purpose To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 in patients newly diagnosed chronic myeloid leukemia phase. Patients Methods A total 476 were randomly assigned 2:1 to (n = 319) or 157) daily. The primary end point was major molecular response (MMR) rate at 12 months. Results At months, differences MMR complete cytogenetic (CCyR) rates not statistically significant (MMR, 46% v 40%; P .2035; CCyR, 70% 66%; .3470)....
Background and Objectives The hypereosinophilic syndrome (HES) may be associated with the fusion of platelet derived growth factor receptor α (PDGFRα) gene FIP1L1 in chromosome 4 coding for a constitutively activated PDGFRα tyrosine kinase. These cases FIP1L1-PDGFRα rearrangement have been reported to very sensitive kinase inhibitor imatinib mesylate.Design Methods A prospective multicenter study idiopathic or primary HES was established 2001 (Study Protocol Registration no. NCT 0027 6929)....
<sup>18</sup>F-FDG PET/CT allows the direct measurement of metabolic tumor burden in a variety different malignancies. The aim this study was to assess whether volume (MTV) determined by could be used prediction progression-free and overall survival multiple myeloma patients. <b>Methods:</b> Forty-seven patients (18 women, 29 men; mean age ± SD, 63 11 y) with stage IIIA disease who had undergone whole-body were retrospectively evaluated. Images underwent 3-dimensional region-of-interest...
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analysis occurred when all completed Week 80 visit discontinued. Objectives included durability of primary response (Week 32 phlebotomy-independent hematocrit control plus ≥35% spleen volume reduction), its components, and that complete hematologic...
BACKGROUND Patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib acquisition of BCR‐ABL kinase domain (KD) mutations. To analyze the changes that second‐generation tyrosine inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken results all KD analyses performed authors' laboratory from January 2004 to 2013. METHODS Interrogation retrieved 450 272 patients Ph+ ALL. Prescreening samples...